Table 3.

Relative hazard of death for metformin use versus nonmetformin or statin use versus nonstatin use in a separate analysis for prediagnosis and postdiagnosis users using time-dependent covariate Cox regression analysis

CharacteristicsNo. of users/nonusersAdjusted HR (95% CI)P
Metformin use
 Prediagnosis users3,110/9,1771.02 (0.97–1.06)a0.52
 Postdiagnosis users285/9,1770.99 (0.87–1.13)a0.88
Statin use
 Prediagnosis users6,833/5,6210.94 (0.91–0.98)b<0.01
 Postdiagnosis users118/5,6210.69 (0.56–0.86)b<0.01
  • aAdjusted for tumor characteristics: stage, grade, tumor size, treatment: resection, radiation, chemotherapy, propensity score for metformin use, and statin use (time-dependent variable).

  • bAdjusted for tumor characteristics: stage, grade, tumor size, treatment: resection, radiation, chemotherapy, propensity score for statin use, and metformin use (time-dependent variable).